Marine Prescription drugs Market to develop by USD 1.56 Bn; Oncology to be the biggest income producing phase
Pharmaceuticals

Marine Prescription drugs Market to develop by USD 1.56 Bn; Oncology to be the biggest income producing phase

NEW YORK, Oct. 28, 2022 /PRNewswire/ — The “Marine Prescription drugs Market by Product and Geography – Forecast and Evaluation 2022-2026” report has been added to Technavio’s providing. The market dimension is anticipated to develop by USD 1.56 billion between 2021 and 2026. As well as, the expansion momentum is anticipated to speed up at a CAGR of seven.73% through the forecast interval, in keeping with Techanavio’s newest market report estimates. This market examine gives full insights into the important thing revenue-generating segments, main progress areas, elements impacting the market dimension, and way more.

This report gives an up-to-date evaluation concerning the most recent tendencies and drivers, the present market state of affairs, and the general market setting. Learn our FREE PDF Pattern Report

Marine Prescription drugs Market 2022-2026: Vendor Evaluation and Scope

To assist companies enhance their market place, the marine prescription drugs market offers an in depth evaluation of round 25 distributors working out there. A few of these distributors embrace Amway Corp., BASF SE, BeyondSpring Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., GlaxoSmithKline Plc, Guardian Industries Corp., Jazz Prescription drugs Plc, Koninklijke DSM NV, Merck KGaA, Nordic Naturals Inc., Pelagia EPAX, Pfizer Inc., Pharma Marine AS, PharmaMar SA, Seagen Inc., and Croda Worldwide Plc.

The report additionally covers the next areas:

Get lifetime entry to our Technavio Insights. Subscribe now to our hottest “Primary Plan” billed yearly at USD 5000. View 100 stories month-to-month and obtain 5 stories per thirty days!

Marine Prescription drugs Market 2022-2026: Segmentation

  • Product 
    • Oncology
    • Cardiovascular
    • Anti-infectives
    • Others

The oncology phase would be the largest contributor to market progress through the forecast interval. At present, the event of checkpoint inhibitors is gaining momentum. These are therapeutic antibodies that facilitate or improve an immune response towards tumor cells. Additionally, there are a number of drug candidates in scientific trials, that are anticipated to drive the expansion of the market through the forecast interval. As well as, the rising availability and growth of the indications by the US FDA are anticipated to drive the expansion of the oncology phase of the worldwide marine prescription drugs market through the forecast interval.

  • Geography 
    • North America
    • Europe
    • Asia
    • Relaxation Of World (ROW)

North America will account for 38% of the market’s progress through the forecast interval. The expansion of the regional market might be attributed to the excessive prevalence of assorted varieties of most cancers and the elevated availability of assorted marine pharmaceutical medicine for the therapy of various types of carcinoma, ache, and CVD. The US and Canada are the important thing markets for marine prescription drugs in North America. Market progress on this area shall be quicker than the expansion of the market within the Remainder of the World (ROW).

Study concerning the contribution of every phase summarized in concise infographics and thorough descriptions. View a FREE PDF Pattern Report

Marine Prescription drugs Market 2022-2026: Key Highlights

  • CAGR of the market through the forecast interval 2022-2026
  • Detailed info on elements that can help marine prescription drugs market progress through the subsequent 5 years
  • Estimation of the marine prescription drugs market dimension and its contribution to the father or mother market
  • Predictions on upcoming tendencies and modifications in client habits
  • The expansion of the marine prescription drugs market
  • Evaluation of the market’s aggressive panorama and detailed info on distributors
  • Complete particulars of things that can problem the expansion of marine prescription drugs market distributors
  • Purchase Report Now

Associated Experiences:

International Mono Vaccine Market 2022-2026: The worldwide mono vaccine market is segmented by kind (meningococcal vaccine, Japanese encephalitis vaccine, hepatitis vaccine, yellow fever vaccine, and others) and geography (North America, Europe, Asia, and the Remainder of the World (ROW)). The meningococcal vaccine phase will generate most income out there. North America will account for a big market share. View Report Snapshot Right here

International Nootropics Market 2022-2026: The worldwide nootropics market is segmented by formulation (capsules, powder, drinks, and others) and geography (North America, Europe, Asia, and the Remainder of the World (ROW)). The capsules phase will generate most income out there. North America will account for a big market share. View Report Snapshot Right here

Marine Prescription drugs Market Scope

Report Protection

Particulars

Web page quantity

120

Base 12 months

2021

Forecast interval

2022-2026

Progress momentum & CAGR

Speed up at a CAGR of seven.73%

Market progress 2022-2026

USD 1.56 billion

Market construction

Concentrated

YoY progress (%)

5.3

Regional evaluation

North America, Europe, Asia, and Remainder of World (ROW)

Performing market contribution

North America at 38%

Key client nations

US, Canada, Germany, UK, and China

Aggressive panorama

Main corporations, aggressive methods, client engagement scope

Firms profiled

Amway Corp., BASF SE, BeyondSpring Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., GlaxoSmithKline Plc, Guardian Industries Corp., Jazz Prescription drugs Plc, Koninklijke DSM NV, Merck KGaA, Nordic Naturals Inc., Pelagia EPAX, Pfizer Inc., Pharma Marine AS, PharmaMar SA, Seagen Inc., and Croda Worldwide Plc

Market Dynamics

Guardian market evaluation, Market progress inducers and obstacles, Quick-growing and slow-growing phase evaluation, COVID-19 affect and future client dynamics, and market situation evaluation for the forecast interval.

Customization purview

If our report has not included the info that you’re on the lookout for, you may attain out to our analysts and get segments custom-made.

Desk of contents:

1 Govt Abstract

  • 1.1 Market overview 
    • Exhibit 01: Govt Abstract – Chart on Market Overview
    • Exhibit 02: Govt Abstract – Information Desk on Market Overview
    • Exhibit 03: Govt Abstract – Chart on International Market Traits
    • Exhibit 04: Govt Abstract – Chart on Market by Geography
    • Exhibit 05: Govt Abstract – Chart on Market Segmentation by Product
    • Exhibit 06: Govt Abstract – Chart on Incremental Progress
    • Exhibit 07: Govt Abstract – Information Desk on Incremental Progress
    • Exhibit 08: Govt Abstract – Chart on Vendor Market Positioning

2 Market Panorama

  • 2.1 Market ecosystem 
    • Exhibit 09: Guardian market
    • Exhibit 10: Market Traits

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 11: Choices of distributors included out there definition
  • 3.2 Market phase evaluation 
    • Exhibit 12: Market segments
  • 3.4 Market outlook: Forecast for 2021-2026 
    • Exhibit 13: Chart on International – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 14: Information Desk on International – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on International Market: Yr-over-year progress 2021-2026 (%)
    • Exhibit 16: Information Desk on International Market: Yr-over-year progress 2021-2026 (%)

4 5 Forces Evaluation

  • 4.1 5 forces abstract 
    • Exhibit 17: 5 forces evaluation – Comparability between 2021 and 2026
  • 4.2 Bargaining energy of consumers 
    • Exhibit 18: Chart on Bargaining energy of consumers – Impression of key elements 2021 and 2026
  • 4.3 Bargaining energy of suppliers 
    • Exhibit 19: Bargaining energy of suppliers – Impression of key elements in 2021 and 2026
  • 4.4 Risk of recent entrants 
    • Exhibit 20: Risk of recent entrants – Impression of key elements in 2021 and 2026
  • 4.5 Risk of substitutes 
    • Exhibit 21: Risk of substitutes – Impression of key elements in 2021 and 2026
  • 4.6 Risk of rivalry 
    • Exhibit 22: Risk of rivalry – Impression of key elements in 2021 and 2026
  • 4.7 Market situation 
    • Exhibit 23: Chart on Market situation – 5 forces 2021 and 2026

5 Market Segmentation by Product

  • 5.1 Market segments 
    • Exhibit 24: Chart on Product – Market share 2021-2026 (%)
    • Exhibit 25: Information Desk on Product – Market share 2021-2026 (%)
  • 5.2 Comparability by Product 
    • Exhibit 26: Chart on Comparability by Product
    • Exhibit 27: Information Desk on Comparability by Product
  • 5.3 Oncology – Market dimension and forecast 2021-2026
    • Exhibit 28: Chart on Oncology – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 29: Information Desk on Oncology – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Oncology – Yr-over-year progress 2021-2026 (%)
    • Exhibit 31: Information Desk on Oncology – Yr-over-year progress 2021-2026 (%)
  • 5.4 Cardiovascular – Market dimension and forecast 2021-2026
    • Exhibit 32: Chart on Cardiovascular – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 33: Information Desk on Cardiovascular – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Cardiovascular – Yr-over-year progress 2021-2026 (%)
    • Exhibit 35: Information Desk on Cardiovascular – Yr-over-year progress 2021-2026 (%)
  • 5.5 Anti-infectives – Market dimension and forecast 2021-2026
    • Exhibit 36: Chart on Anti-infectives – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 37: Information Desk on Anti-infectives – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 38: Chart on Anti-infectives – Yr-over-year progress 2021-2026 (%)
    • Exhibit 39: Information Desk on Anti-infectives – Yr-over-year progress 2021-2026 (%)
  • 5.6 Others – Market dimension and forecast 2021-2026
    • Exhibit 40: Chart on Others – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 41: Information Desk on Others – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 42: Chart on Others – Yr-over-year progress 2021-2026 (%)
    • Exhibit 43: Information Desk on Others – Yr-over-year progress 2021-2026 (%)
  • 5.7 Market alternative by Product 
    • Exhibit 44: Market alternative by Product ($ million)

6 Buyer Panorama

  • 6.1 Buyer panorama overview 
    • Exhibit 45: Evaluation of value sensitivity, lifecycle, buyer buy basket, adoption charges, and buy standards

7 Geographic Panorama

  • 7.1 Geographic segmentation 
    • Exhibit 46: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 47: Information Desk on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparability 
    • Exhibit 48: Chart on Geographic comparability
    • Exhibit 49: Information Desk on Geographic comparability
  • 7.3 North America – Market dimension and forecast 2021-2026
    • Exhibit 50: Chart on North America – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 51: Information Desk on North America – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on North America – Yr-over-year progress 2021-2026 (%)
    • Exhibit 53: Information Desk on North America – Yr-over-year progress 2021-2026 (%)
  • 7.4 Europe – Market dimension and forecast 2021-2026
    • Exhibit 54: Chart on Europe – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 55: Information Desk on Europe – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Europe – Yr-over-year progress 2021-2026 (%)
    • Exhibit 57: Information Desk on Europe – Yr-over-year progress 2021-2026 (%)
  • 7.5 Asia – Market dimension and forecast 2021-2026
    • Exhibit 58: Chart on Asia – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 59: Information Desk on Asia – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on Asia – Yr-over-year progress 2021-2026 (%)
    • Exhibit 61: Information Desk on Asia – Yr-over-year progress 2021-2026 (%)
  • 7.6 Remainder of World (ROW) – Market dimension and forecast 2021-2026
    • Exhibit 62: Chart on Remainder of World (ROW) – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 63: Information Desk on Remainder of World (ROW) – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on Remainder of World (ROW) – Yr-over-year progress 2021-2026 (%)
    • Exhibit 65: Information Desk on Remainder of World (ROW) – Yr-over-year progress 2021-2026 (%)
  • 7.7 US – Market dimension and forecast 2021-2026
    • Exhibit 66: Chart on US – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 67: Information Desk on US – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on US – Yr-over-year progress 2021-2026 (%)
    • Exhibit 69: Information Desk on US – Yr-over-year progress 2021-2026 (%)
  • 7.8 Germany – Market dimension and forecast 2021-2026
    • Exhibit 70: Chart on Germany – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 71: Information Desk on Germany – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on Germany – Yr-over-year progress 2021-2026 (%)
    • Exhibit 73: Information Desk on Germany – Yr-over-year progress 2021-2026 (%)
  • 7.9 China – Market dimension and forecast 2021-2026
    • Exhibit 74: Chart on China – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 75: Information Desk on China – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on China – Yr-over-year progress 2021-2026 (%)
    • Exhibit 77: Information Desk on China – Yr-over-year progress 2021-2026 (%)
  • 7.10 UK – Market dimension and forecast 2021-2026
    • Exhibit 78: Chart on UK – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 79: Information Desk on UK – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 80: Chart on UK – Yr-over-year progress 2021-2026 (%)
    • Exhibit 81: Information Desk on UK – Yr-over-year progress 2021-2026 (%)
  • 7.11 Canada – Market dimension and forecast 2021-2026
    • Exhibit 82: Chart on Canada – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 83: Information Desk on Canada – Market dimension and forecast 2021-2026 ($ million)
    • Exhibit 84: Chart on Canada – Yr-over-year progress 2021-2026 (%)
    • Exhibit 85: Information Desk on Canada – Yr-over-year progress 2021-2026 (%)
  • 7.12 Market alternative by geography 
    • Exhibit 86: Market alternative by geography ($ million)

8 Drivers, Challenges, and Traits

  • 8.3 Impression of drivers and challenges 
    • Exhibit 87: Impression of drivers and challenges in 2021 and 2026

9 Vendor Panorama

  • 9.2 Vendor panorama 
    • Exhibit 88: Overview on Criticality of inputs and Components of differentiation
  • 9.3 Panorama disruption 
    • Exhibit 89: Overview on elements of disruption
  • 9.4 Trade dangers 
    • Exhibit 90: Impression of key dangers on enterprise

10 Vendor Evaluation

  • 10.1 Distributors lined 
    • Exhibit 91: Distributors lined
  • 10.2 Market positioning of distributors 
    • Exhibit 92: Matrix on vendor place and classification
  • 10.3 BeyondSpring Inc. 
    • Exhibit 93: BeyondSpring Inc. – Overview
    • Exhibit 94: BeyondSpring Inc. – Product / Service
    • Exhibit 95: BeyondSpring Inc. – Key choices
  • 10.4 BioMarin Pharmaceutical Inc. 
    • Exhibit 96: BioMarin Pharmaceutical Inc. – Overview
    • Exhibit 97: BioMarin Pharmaceutical Inc. – Product / Service
    • Exhibit 98: BioMarin Pharmaceutical Inc. – Key choices
  • 10.5 Bristol Myers Squibb Co. 
    • Exhibit 99: Bristol Myers Squibb Co. – Overview
    • Exhibit 100: Bristol Myers Squibb Co. – Product / Service
    • Exhibit 101: Bristol Myers Squibb Co. – Key choices
  • 10.6 Eisai Co. Ltd. 
    • Exhibit 102: Eisai Co. Ltd. – Overview
    • Exhibit 103: Eisai Co. Ltd. – Enterprise segments
    • Exhibit 104: Eisai Co. Ltd. – Key choices
    • Exhibit 105: Eisai Co. Ltd. – Section focus
  • 10.7 GlaxoSmithKline Plc 
    • Exhibit 106: GlaxoSmithKline Plc – Overview
    • Exhibit 107: GlaxoSmithKline Plc – Enterprise segments
    • Exhibit 108: GlaxoSmithKline Plc – Key information
    • Exhibit 109: GlaxoSmithKline Plc – Key choices
    • Exhibit 110: GlaxoSmithKline Plc – Section focus
  • 10.8 Jazz Prescription drugs Plc 
    • Exhibit 111: Jazz Prescription drugs Plc – Overview
    • Exhibit 112: Jazz Prescription drugs Plc – Product / Service
    • Exhibit 113: Jazz Prescription drugs Plc – Key information
    • Exhibit 114: Jazz Prescription drugs Plc – Key choices
  • 10.9 Nordic Naturals Inc. 
    • Exhibit 115: Nordic Naturals Inc. – Overview
    • Exhibit 116: Nordic Naturals Inc. – Product / Service
    • Exhibit 117: Nordic Naturals Inc. – Key choices
  • 10.10 Pfizer Inc. 
    • Exhibit 118: Pfizer Inc. – Overview
    • Exhibit 119: Pfizer Inc. – Product / Service
    • Exhibit 120: Pfizer Inc. – Key information
    • Exhibit 121: Pfizer Inc. – Key choices
  • 10.11 PharmaMar SA 
    • Exhibit 122: PharmaMar SA – Overview
    • Exhibit 123: PharmaMar SA – Enterprise segments
    • Exhibit 124: PharmaMar SA – Key information
    • Exhibit 125: PharmaMar SA – Key choices
    • Exhibit 126: PharmaMar SA – Section focus
  • 10.12 Seagen Inc. 
    • Exhibit 127: Seagen Inc. – Overview
    • Exhibit 128: Seagen Inc. – Product / Service
    • Exhibit 129: Seagen Inc. – Key choices

11 Appendix

  • 11.2 Inclusions and exclusions guidelines 
    • Exhibit 130: Inclusions guidelines
    • Exhibit 131: Exclusions guidelines
  • 11.3 Foreign money conversion charges for US$ 
    • Exhibit 132: Foreign money conversion charges for US$
  • 11.4 Analysis methodology 
    • Exhibit 133: Analysis methodology
    • Exhibit 134: Validation strategies employed for market sizing
    • Exhibit 135: Info sources
  • 11.5 Checklist of abbreviations 
    • Exhibit 136: Checklist of abbreviations

About Us

Technavio is a number one world know-how analysis and advisory firm. Their analysis and evaluation give attention to rising market tendencies and offers actionable insights to assist companies determine market alternatives and develop efficient methods to optimize their market positions. With over 500 specialised analysts, Technavio’s report library consists of greater than 17,000 stories and counting, protecting 800 applied sciences, spanning throughout 50 nations. Their shopper base consists of enterprises of all sizes, together with greater than 100 Fortune 500 corporations. This rising shopper base depends on Technavio’s complete protection, in depth analysis, and actionable market insights to determine alternatives in present and potential markets and assess their aggressive positions inside altering market eventualities.

Contact

Technavio Analysis
Jesse Maida
Media & Advertising and marketing Govt
US: +1 844 364 1100
UK: +44 203 893 3200
E mail: [email protected]
Web site: www.technavio.com/

SOURCE Technavio